Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation

University Hospital, Brest300 enrolled

Overview

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Rheumatoid Arthritis COVID

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Rheumatoid arthritis satisfying ACR/EULAR criteria * Ongoing DMARD therapy Exclusion Criteria: * Inhability to consent

Locations (1)

CHRU de Brest

Brest, France

Outcomes

Primary Outcomes

Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis

Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD

Time frame: 1 Day